Cannabigerol (cbg) products and methods of use
AssigneeBazelet Health Systems, Inc.
InventorsMichael Elzufon, Howard Hoffberg
Life of this patent
Estimating the term…
Abstract
A cannabinoid composition having antiinflammatory and antineoplastic activity, comprising a full spectrum extract of a plant of genus Cannabis comprising at least 5% by weight cannabigerol, comprising Cannabis terpenes and Cannabis flavonoids, and substantially without cannabidiol and tetrahydrocannabinol. The composition may be a pharmaceutically acceptable formulation for oral, sublingual, inhaled, vaporized, or smoked administration. The formulation may include absorption or pharmacological enhancers e.g., curcumin, resveratrol, quercitin, piperine and/or N-alkylamides. The composition has anti-inflammatory properties beneficial as a prophylaxis or therapy of symptoms due to viral infection, and tumor growth.
Claims20
A method of treating or preventing a human inflammatory process, comprising administering to a person a pharmaceutically acceptable full spectrum or broad spectrum extract of a plant of genus Cannabis comprising at least 5% by weight of at least one of cannabigerol, cannabigerol acid, cannabigerovarin, and cannabigerovarin acid;
- together with Cannabis terpenes and Cannabis flavonoids in an effective amount to treat the neoplasia.
A method of treating an inflammatory disorder associated with neoplasia, comprising administering to a human having an inflammatory process an effective dose of a pharmaceutically effective formulation comprising a full or broad spectrum extract of a plant of genus Cannabis comprising:
- at least 5% by weight of a cannabinoid selected from the group consisting of at least one of cannabigerol, cannabigerol acid, cannabigerovarin, and cannabigerovarin acid, predominantly in an acid form;
- Cannabis terpenes;
- and
- Cannabis flavonoids;
- substantially without cannabidiol or tetrahydrocannabinol.
A method of treating an inflammatory or neoplastic condition of a mammal, comprising:
- determining occurrence of the inflammatory or neoplastic condition of the mammal;
- administering to the mammal a pharmaceutically acceptable formulation comprising at least one cannabinoid selected from the group consisting of cannabigerol, cannabigerol acid, cannabigerovarin, and cannabigerovarin acid, substantially without cannabidiol and tetrahydrocannabinol;
- and
- concurrently administering to the mammal at least one endocannabinoid,
- the at least one cannabinoid and the at least one cannabinoid being administered in an effective amount to treat the inflammatory or neoplastic condition.
Dependencies are inferred from the claim text.